| Budget Amount *help |
¥19,760,000 (Direct Cost: ¥15,200,000、Indirect Cost: ¥4,560,000)
Fiscal Year 2010: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2009: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2008: ¥11,440,000 (Direct Cost: ¥8,800,000、Indirect Cost: ¥2,640,000)
|
|---|
| Research Abstract |
In this study, we attempted to develop gene therapeutic technology for diabetes by production of insulin in skin and muscle via noninvasive transdermal delivery of artificial gene delivery system MEND. We succeeded the noninvasive transdermal delivery of MEND by jet-injection, and induction of sustained gene expression in the skin. We constructed preproinsulin plasmid DNA, and confirmed significant expression of the mRNA in the culture cells and skin. Moreover, increment of insulin production in diabetes-model mice treated with MEND.
|
